Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-24-021677
Filing Date
2024-05-08
Accepted
2024-05-08 16:10:40
Documents
80
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q pcvx-20240331.htm   iXBRL 10-Q 1502993
2 EX-31.1 pcvx-20240331x10qxexx311.htm EX-31.1 10548
3 EX-31.2 pcvx-20240331x10qxexx312.htm EX-31.2 10559
4 EX-32.1 pcvx-20240331x10qxexx321.htm EX-32.1 7137
  Complete submission text file 0001628280-24-021677.txt   7231834

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT pcvx-20240331.xsd EX-101.SCH 63444
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT pcvx-20240331_cal.xml EX-101.CAL 78135
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT pcvx-20240331_def.xml EX-101.DEF 242864
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT pcvx-20240331_lab.xml EX-101.LAB 674555
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT pcvx-20240331_pre.xml EX-101.PRE 468302
84 EXTRACTED XBRL INSTANCE DOCUMENT pcvx-20240331_htm.xml XML 857446
Mailing Address 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070
Business Address 825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CA 94070 650-837-0111
Vaxcyte, Inc. (Filer) CIK: 0001649094 (see all company filings)

EIN.: 464233385 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39323 | Film No.: 24926116
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)